期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗人类免疫缺陷病毒新药：D-D4FC

Anti-HIV new drug:D-D4FC
下载PDF
导出
摘要 β-D-2′,3′-双脱氢双脱氧-5-氟胞苷(D-D4FC)是一种新型抗人类免疫缺陷病毒(HIV)的核苷类药物,可有效抑制HIV病毒株及其变异株。D-D4FC与大多数抗病毒抑制药联合用药无相互抑制作用,几乎无细胞毒性,是一种极具潜力的抗HIV药物。目前,D-D4FC正在美国,法国和德国进行Ⅱ期临床试验,其Ⅲ期临床试验也正计划启动。 β-D-2＇ , 3＇-didehydro-2＇ , 3＇-dideoxy-5-fluoroeytidine （D-D4FC） is a new nucleoside analogue with combination potency of inhibition against wild-type HIV and its variants. D-D4FC possesses no correlative resistance with almost no toxicity on mitoehondrion in combination application with the most other antiviral inhibitors. Meanwhile, D-D4FC is carrying on its phase Ⅱ clinical trial in America, France and Germany and the phase Ⅲ is now planning in progress.
作者 蒋波 戚娜 朱利民
机构地区 东华大学生物科学与技术研究所
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2008年第5期369-372,共4页 Chinese Journal of New Drugs and Clinical Remedies
基金 上海市科委浦江人才计划资助项目(05PJ14014)
关键词 获得性免疫缺陷综合征 HIV 抗HIV药 药物疗法 D—D4FC acquired immunodeficiency syndrome HIV anti-HIV agents drug theray D-D4FC
分类号 R978.7 [医药卫生—药品] R512.91 [医药卫生—内科学]
  • 相关文献

参考文献16

  • 1de CLERCQ E.Antiviral drugs in current clinical use[J]. J Clin Virol, 2004, 30(2): 115-133.
  • 2de CLERCQ E. New developments in anti-HIV chemotherapy[J]. Biochim Biophys Acta, 2002, 1587(2-3): 258-275.
  • 3SCHINAZI RF, HERNANDEZ-SANTIAGO BI, HURWITZ SJ. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses[J]. Antiviral Res, 2006, 71(2-3): 322-334.
  • 4张海雁,姜和,蔡绍皙,谢东.人类免疫缺陷病毒进入抑制剂的临床开发与应用[J].中国新药与临床杂志,2005,24(12):977-981. 被引量：3
  • 5张宏梁,肖宏.临床试验阶段的抗人免疫缺陷病毒化学药物研究进展[J].中国新药与临床杂志,2006,25(5):388-392. 被引量：3
  • 6SCHINAZI RF, MELLORS J, BAZMI H, et al. DPC 817:a cytidine nucleoside analog with activity against zidovudine-and lamivudine-resistant viral variants[J]. Antimicrob Agents Chemother, 2002, 46(5): 1394-1401.
  • 7RAY AS, SCHINAZI RF, MURAKAMI E, et al. Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase [J].Antivir Chem Chemother, 2003, 14(3): 115-125.
  • 8CHONG Y, CHOO H, CHU CK.Effects of fluorine substitution of cytosine analogues on the binding affinity to HIV-1 reverse transcriptase[J]. Bioorg Med Chem Lett, 2004, 14(2): 437- 440.
  • 9MURAKAMI E, RAY AS, SCHINAZI RF, et al. Investigating the effects of stereochemistry on incorporation and removal of 5- fluorocytidine analogs by mitochondrial DNA polymerase gamma:comparison of D-and L-D4FC-TP[J]. Antiviral Res, 2004, 62(1): 57-64.
  • 10RAY AS, MURAKAMI E,PETERSON CN, et al. Interactions of enantiomers of 2', 3'-didehydro-2', 3'-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase [J]. Antiviral Res, 2002, 56(3): 189-205.

二级参考文献126

  • 1Mitsuya H, Weinhold K J, Kent J. et al. 3 '-Azido-3 '-deoxy-thymidine (BW AS09U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type Ⅲ/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA, 1985, 82: 7096-7100.
  • 2Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type Ⅲ/lymphadenopathy-associated virus(HTLV-Ⅲ/LAV) by 2’ 3'-di-deoxynucleosides. Proc Natl Acad Sci USA, 1986, 83(6): 1911-1915.
  • 3Yarchoan R, Mitsuya H, Thomas R V. et al. In vivo activity against HIV and favorable toxicity profile of 2,3'-Dideoxyinosine. Science,1989, 245:412-..415.
  • 4Mansuri M M, Starett J E, Ghazzouli i, et al. 1-(2, 3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent. J Med Chem, 1989, 32(2): 461-466.
  • 5Katlama C, Clotet B, Plettenberg A, et al. Abacavir sulfate was first launched in 1999 by Glaxo Wellcome as Ziagen in the US for the treatment of H1V infection, in combination with other antiretroviral agent. AIDS, 2000, 14:781-789.
  • 6Chang C -N, Doong S -L, Zhou J H, et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2', 3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication.J Biol Chem, 1992, 267(20): 13938-13942.
  • 7Doong S -L, Tasi C -H, Schinazi R F, et al. Inhibition of the replication of hepatitis B virus in vitro by 29, 39-dideoxy-391 thiacytidine and related analogues. Proc Natl Acad Sci USA, 1991, 88:8495-8499.
  • 8Dienstag J L, Perrillo R P, Schiff E R, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. New Engl J Med,1995, 333:1657-1661.
  • 9Naesens L, Balzarini J, Bischofberger N, et al. Antiretroviral activity and pharmacokinetics in mice of oral his (pivaloylmethyl)-9-(2-phosphonylmethoxy-ethyl)adenine, the his (pivaloyloxymethyl) ester prodrug of 9-(2-phosphonyl methoxyethyl)adenine. Antimicrob Agents Chemother. 1996.40:22-28.
  • 10Yokota T, Konno K, Shigeta S, et al. Inhibitory effects of acyclic nucleoside phosphonate analogs on hepatitis B virus DNA synthesis in HB611 cells. Antiviral Chem Chemother, 1994, 5:57--63.

共引文献7

中国新药与临床杂志
2008年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部